新基药目录要来了？管理办法提出与集采等政策衔接

Core Viewpoint - The new "National Essential Medicines Directory Management Measures" aims to improve the management mechanism of essential medicines, aligning with policies on supply, tiered diagnosis and treatment, centralized procurement, and reimbursement [1][4]. Group 1: Key Revisions in the New Measures - The new measures propose six areas of revision, including enhancing the directory management mechanism and emphasizing the clinical value of medicines based on changes in disease spectrum, clinical application practices, and new drug approvals [1][4]. - The directory formulation process involves establishing an expert database, consulting experts for technical evaluations, and conducting comprehensive reviews to finalize the directory [3][6]. Group 2: Historical Context and Current Status - The current essential medicines directory, last updated in 2018, includes 685 varieties of medicines, with 417 chemical and biological products and 268 traditional Chinese medicines [4]. - The new measures signal a significant change in the essential medicines directory, although the updated list has not yet been published. The directory will undergo regular assessments and adjustments, ideally every three years [4][5]. Group 3: Industry Implications - Pharmaceutical companies are particularly interested in the criteria for updating the essential medicines list, especially regarding the integration of centralized procurement policies [5][6]. - The status of a medicine as part of the essential medicines directory can significantly impact its market access and the competitive landscape for pharmaceutical companies [5][6].